PAI
KZR

Palo Alto Investors’s Kezar Life Sciences KZR Stock Holding History

Palo Alto Investors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-65,620
Closed -$781K – 35
2023
Q3 		$781K Hold
65,620
– – 0.07% 27
2023
Q2 		$1.61M Hold
65,620
– – 0.13% 26
2023
Q1 		$2.05M Hold
65,620
– – 0.17% 22
2022
Q4 		$4.62M Hold
65,620
– – 0.39% 19
2022
Q3 		$5.65M Hold
65,620
– – 0.45% 21
2022
Q2 		$5.43M Hold
65,620
– – 0.47% 23
2022
Q1 		$10.9M Hold
65,620
– – 0.84% 18
2021
Q4 		$11M Hold
65,620
– – 0.7% 22
2021
Q3 		$5.67M Hold
65,620
– – 0.34% 26
2021
Q2 		$3.56M Hold
65,620
– – 0.2% 29
2021
Q1 		$3.91M Buy
65,620
+10,799
+20% +$631K 0.22% 30
2020
Q4 		$2.86M Buy
54,821
+5,889
+12% +$328K 0.15% 31
2020
Q3 		$2.37M Buy
48,932
+28,423
+139% +$1.36M 0.13% 32
2020
Q2 		$1.06M Buy
+20,509
New +$1.03M 0.06% 33

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palo Alto Investors's KZR Position: Q4 2023 in Review

Palo Alto Investors sold out of Kezar Life Sciences (KZR) in Q4 2023, closing a stake of 65,620 shares — an estimated $781K sold.

Palo Alto Investors first reported a position in KZR in Q2 2020 and held it in 14 quarters. The position peaked at $11M in Q4 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q4 2023.

  • Palo Alto Investors reported no remaining Kezar Life Sciences position as of Q4 2023 after selling out during the quarter.
  • Palo Alto Investors sold 65,620 Kezar Life Sciences shares in Q4 2023, an estimated $781K.
  • Palo Alto Investors first reported a position in Kezar Life Sciences in Q2 2020 and held it in 14 quarters.
  • Palo Alto Investors's Kezar Life Sciences position peaked at $11M in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2023.

Based on Palo Alto Investors's 13F filing for Q4 2023, filed 14 Feb 2024.